The pCODR Expert Review Committee (pERC) has recommended against the funding of ofatumumab acetate (Arzerra) when used in combination with chlorambucil by patients with previously untreated chronic lymphocytic leukaemia and in whom the use of fludarabine phosphate is considered to be inappropriate.

This is an initial decision; a final decision will be issued in due course.

For more details, go to: http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr-arzerra-cll-in-rec.pdf